Proposed Regulation for Complementary Health Products in Singapore
Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.
Mandatory registration in swissdamed for medical devices and IVDs replaces existing notification procedures with effect from 1 July 2026.
Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Introduction of mandatory device registration in the swissdamed UDI Devices module; replacement of class I notifications; immediate registration required for vigilance-reportable incidents.
MAHs and manufacturers must use swissdamed for device registration and vigilance-related reporting (incidents, FSCAs, trends) from 1 July 2026 without a transitional period.
Manufacturers must adapt their processes to ensure registration before market placement.
Mandatory registration of medical devices in swissdamed
The introduction of mandatory registration in swissdamed from 1 July 2026 replaces prior notification procedures for medical devices and IVDs.
This regulatory change enhances market surveillance and ensures that medical devices comply with safety standards before entering the market.
Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.
Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.
MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.
Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.
Ensure compliance with updated SUSAR reporting timelines (15 days), notify SFDA of Phase IV trials within 20 working days post-IRB approval, and prepare for the financial fee of 15,000 Saudi Riyals for clinical trial evaluations.